Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.

ABSTRACT:

SUBMITTER: Scarfo L 

PROVIDER: S-EPMC9631708 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature